# EDGAR Filing Document

**Accession Number:** 0001618500
**File Stem:** 0001213900-23-005238
**Filing Date:** 2023-1
**Character Count:** 6589
**Document Hash:** 1769132dbbf1c550ef918c7383732dae
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-23-005238.hdr.sgml**: 20230126

**ACCESSION NUMBER**: 0001213900-23-005238

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230126

**FILED AS OF DATE**: 20230126

**DATE AS OF CHANGE**: 20230126

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Medigus Ltd.
- **CENTRAL INDEX KEY:** 0001618500
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37381
- **FILM NUMBER:** 23554985

**BUSINESS ADDRESS:**
- **STREET 1:** 3 HANECHOSHET STREET, BUILDING B
- **CITY:** TEL AVIV
- **STATE:** L3
- **ZIP:** 6971068
- **BUSINESS PHONE:** 972722602211

**MAIL ADDRESS:**
- **STREET 1:** 3 HANECHOSHET STREET, BUILDING B
- **CITY:** TEL AVIV
- **STATE:** L3
- **ZIP:** 6971068

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION<br> Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16<br> UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of January 2023

Commission File Number 001-37381

**MEDIGUS LTD.**<br> (Translation of registrant's name into English)

**3 HaNechoshet Street, Building B, 6971068, Israel**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): __

**EXPLANATORY NOTE**

On January 26, 2023, Medigus Ltd. issued a press release titled: "Medigus: Gix Media Increases Holdings in Cortex Media Group to 80% of its Share Capital." A copy of this press release is furnished herewith as Exhibit 99.1.

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| 99.1 | [Press release dated January 26, 2023](ea172245ex99-1_medigusltd.htm) |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **MEDIGUS LTD.** | **MEDIGUS LTD.** |
| Date: January 26, 2023 | By: | /s/ Tali Dinar |
|  |  | Tali Dinar |
|  |  | Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**Medigus: Gix Media Increases Holdings in Cortex Media Group to 80% of its Share Capital** 

 

**Tel Aviv, Israel, Jan. 26, 2023 (GLOBE NEWSWIRE) --** Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle and charging solutions, today announced that Gix Media Ltd. ("Gix Media"), a subsidiary of Medigus affiliate, Gix Internet (in which Medigus holds 42.25%) (TASE: GIX), a global marketing technology (MarTech) solutions company for online performance-based-marketing, acquired an additional 10% of Cortex Media Group Ltd. ("Cortex"), a digital publishing company, increasing its holdings to 80% of the share capital of Cortex on a fully diluted basis (the "Subsequent Purchase").

The Subsequent Purchase was completed at a valuation of Cortex of approximately $27 million in exchange for consideration consisting of $2.7 million in cash.

The Subsequent Purchase follows Gix Media's initial purchase of 70% of Cortex's share capital in October 2021 (the "Initial Purchase"). At the Initial Purchase, Cortex was valued at $16 Million and the increase in Cortex's current valuation is primarily due to an increase in its results and activity and its improved financials.

During the period following Gix Media's Initial Purchase, Gix Media's revenues grew by 176% to $66.1 million during the nine months ending September 30, 2022, as compared to the same period in 2021.

Gix Media intends to finance the Subsequent Purchase through both cash and the expansion of a $1.5 million loan.

**<u>About Medigus</u>**

Based in Israel, Medigus Ltd. (Nasdaq: MDGS) is a technology company focused on innovative growth partnerships, mainly in advanced medical solutions, digital commerce and electric vehicle markets. Medigus' affiliations in the medical solutions arena include ownership in Polyrizon Ltd. and ownership in industry 4.0 company, ScoutCam Inc. The Company's affiliates in digital commerce include Gix Internet Ltd., Jeffs' Brands Ltd. and Eventer Technologies Ltd. In the electric vehicle market, Charging Robotics Ltd. and Revoltz Ltd. are also part of the Company's portfolio of technology solution providers. To learn more about Medigus' advanced technologies, please visit: http://www.medigus.com/.

**<u>Forward-Looking Statements</u>**

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. Because such statements deal with future events and are based on Medigus' current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements could differ materially from those described in or implied by the statements in this press release.

The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed in any filings with the SEC. Except as otherwise required by law, Medigus undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Medigus is not responsible for the contents of third-party websites.

**Company Contact:**

Tali Dinar

Chief Financial Officer

+972-8-6466-880

ir@medigus.com

**Investor Relations Contact:**

Michal Efraty

Investor Relations, Israel

+972-(0)52-3044404<br> michal@efraty.com